Developmental Funds have had a high scientific impact during the project period. Developmental Funds were used to support the external recruitment of nine New Investigators who have brought scientific expertise in high priority areas, the development of a new Circulating Tumor Cell Shared Resource that provides unique technology and exceptional scientific expertise in this burgeoning area, and the funding of a pilot project that has contributed to our growing Adolescent and Young Adult Program. These accomplishments were funded by a total of $545,000 in Developmental Funds during the four year project period (approximately $130,000 per year): $425,000 for New Investigators, $50,000 for Pilot Projects and $70,000 for Developing Shared Resources. In this application, we request a budget of $450,000 per year for Developmental Funds. Of this amount, $200,000 will be allocated for the recruitment of New Investigators in high priority research areas, $200,000 for the development of a new Bioinformatics Shared Resource, and $50,000 for novel pilot projects with the potential to secure external funding. Developmental Funds will be critical to growing our research base and increasing collaborative research in targeted areas. The focus of annual pilot project program, priorities for New Investigators support, and plans for Shared Resources will continue to be developed with input from Senior and Program Leaders and guided by advice from our External Advisory Board.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-44
Application #
9607926
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244

Showing the most recent 10 out of 842 publications